Salvina

Salvina Therapeutics has unlocked a novel epitope for selectively targeting TNF and other TNF superfamily members, resulting in the generation of antibodies with a highly innovative mode of action. These have the potential to significantly improve the benefit/risk ratio of TNF targeting in certain diseases and enable bispecific therapies that have not been developable to date.